ArticleBrain and behavior2025
Serum Nox1 and Gper Levels in Patients With Generalized Anxiety Disorder: A Cross-Sectional Study in Turkiye.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Peripheral S-(PGJBMC psychiatry · 2026Article
- Sex differences in G protein-coupled estrogen receptor-mediated mechanisms in preclinical models of anxiety and fear.Frontiers in behavioral neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough the etiopathogenesis of generalized anxiety disorder (GAD) is not fully known, it is suggested that oxidative stress (OS) and estrogen play important roles. NADPH oxidase 1 (NOX1) is from the NADPH oxidase (NOX) family, which is known as a main source of reactive oxygen species (ROS). The G protein-coupled estrogen receptor (GPER) is a novel estrogen receptor that mediates the non-genomic rapid effects of estrogen. Recent work has shown GPER to be associated with OS, but it has not to our knowledge been examined in patient samples with GAD.
methodWe conducted a study comparing serum NOX1 and GPER levels of patients with GAD and healthy controls (HCs) matched for age, sex, and body mass index (BMI). FINDING: We found increased NOX1 and decreased GPER levels in patients with GAD compared with HCs. In addition, we showed that serum NOX1 levels have very good diagnostic performance for patients with GAD. We observed a weak positive correlation between serum NOX1 levels and GPER levels in the patient group.
conclusionAlthough we believe these results are important for a better understanding of the role of OS and estrogen in GAD patients, longitudinal studies should be performed in larger samples of GAD patients grouped by severity of symptoms.We investigated the levels of NOX1 and GPER in patients with GAD. We found increased NOX1 and decreased GPER levels in patients with GAD compared to healthy controls. In addition, we showed that serum NOX1 levels have very good diagnostic performance for patients with GAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.